VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF‑CTCL) in patients who have received prior skin-directed therapy

VALCHLOR Support and resources

VALCHLOR Support and resources can help patients start and stay on therapy

VALCHLOR Support offers:

  • Assistance with insurance verifications, prior authorizations, and appeals
  • Financial assistance for eligible patients
  • Disease and product information for patients
  • Prescription management and refill instructions
  • Direct shipping to patients

For more information, please call 1-855-4-VALCHLOR (1-855-482-5245).

Educating your patients about Stage lA and lB mycosis fungoides-type cutaneous T-cell lymphoma

You can find additional information to help you educate your patients at the following web sites:

Cutaneous Lymphoma Foundation: clfoundation.org

Lymphoma Research Foundation: lymphoma.org

Leukemia & Lymphoma Society: lls.org

Helsinn offers links to third-party web sites that may assist you in locating other useful information. Helsinn does not control and is not responsible for the content of any linked third-party web site, and hereby disclaims any and all liability and responsibility for these resources.

We also offer a comprehensive informational brochure that you may provide to your patients in your office. Download the brochure here

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine.

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

The most common adverse reactions (≥5%) were dermatitis (56%), pruritus (20%), bacterial skin infection (11%), skin ulceration or blistering (6%), and hyperpigmentation (5%). These reactions may be moderately severe or severe. Elderly patients aged 65 and older may be more susceptible. Depending on severity, treatment reduction, suspension, or discontinuation may be required.

DOSING AND APPLICATION

VALCHLOR is for topical dermatologic use only. Apply a thin film of gel once daily to affected areas of the skin. VALCHLOR is a cytotoxic drug and special handling and disposal procedures should be followed during use. Caregivers must wear disposable nitrile gloves when applying VALCHLOR. Patients and caregivers must wash hands thoroughly after handling or applying VALCHLOR.

To report SUSPECTED ADVERSE REACTIONS, contact Helsinn Therapeutics (U.S.), Inc., at 1-855-4-VALCHLOR (1-855-482-5245) or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see VALCHLOR full Prescribing Information.